Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28413128.
- Also identified by DOI 10.1016/j.eururo.2017.03.047.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint inhibitors are a new treatment option in metastatic urothelial cancer on the basis of available phase 2 and 3 trials. Predictive biomarkers are needed. These should go beyond PD-L1 expression, which is showing inconsistent results across trials.
Medical subject headings
- Antineoplastic Agents, Immunological
- Signal Transduction
- Urologic Neoplasms
- Urothelium